Diaceutics PLC
Simbolis: DIUXF
PNK
1.3672
USDRinkos kaina šiandien
-124.8659
P/E santykis
2.7906
PEG koeficientas
123.70M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Diaceutics PLC (DIUXF) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 19.8 | 19.7 | 25.3 | |||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.net-receivables | 0 | 10.4 | 10 | 7.8 | |||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-current-assets | 0 | 0.6 | 0.4 | 0.6 | |||||||
balance-sheet.row.total-current-assets | 0 | 30.9 | 30.1 | 33.6 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2.1 | 2.1 | 0.2 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.long-term-investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0.3 | |||||||
balance-sheet.row.other-non-current-assets | 0 | -17.1 | -14.7 | -9.2 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 17.4 | 15 | 9.9 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.account-payables | 0 | 0.8 | 0.5 | 0.5 | |||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.3 | 0.1 | |||||||
balance-sheet.row.tax-payables | 0 | 0.4 | 0.3 | 0.8 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 1.2 | 1.3 | 0 | |||||||
Deferred Revenue Non Current | 0 | 0 | -0.4 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 2.5 | 1.6 | 2 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2 | 1.7 | 0.4 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 1.3 | 1.4 | 0 | |||||||
balance-sheet.row.total-liab | 0 | 5.7 | 4.4 | 3.3 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0.3 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 0.2 | 0.2 | 0.2 | |||||||
balance-sheet.row.retained-earnings | 0 | 5.3 | 4.1 | 3.2 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | -0.3 | 0 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 36.9 | 36.4 | 36.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.total-debt | 0 | 1.3 | 1.6 | 0.1 | |||||||
balance-sheet.row.net-debt | 0 | -18.5 | -18.1 | -25.1 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 0.6 | 0.5 | -0.7 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 1.3 | -0.5 | -0.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0.5 | 0.4 | 0.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -0.3 | -1.7 | 0.5 | |||||||
cash-flows.row.account-receivables | 0 | -1.6 | -1.5 | 0.5 | |||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.account-payables | 0 | 1.3 | -0.2 | -0.1 | |||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0.1 | 0 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-investing-activites | 0 | 0.1 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4.8 | -5.6 | -6.3 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | |||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0 | 19.6 | |||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -0.2 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -0.2 | -0.3 | 19.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -0.3 | 0 | |||||||
cash-flows.row.net-change-in-cash | 0 | 0.2 | -5.6 | 13.5 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 19.8 | 19.7 | 25.3 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 19.7 | 25.3 | 11.7 | |||||||
cash-flows.row.operating-cash-flow | 0 | 5.1 | 0.6 | 0.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.free-cash-flow | 0 | 0.2 | -5 | -6 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 19.5 | 13.9 | 12.7 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 2.8 | 3.2 | 3.2 | |||||||
income-statement-row.row.gross-profit | 0 | 16.7 | 10.7 | 9.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.operating-expenses | 0 | 16.2 | 10.2 | 9.7 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 18.9 | 13.4 | 13 | |||||||
income-statement-row.row.interest-income | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | 0.6 | 0.6 | -0.7 | |||||||
income-statement-row.row.income-before-tax | 0 | 0.6 | 0.5 | -0.7 | |||||||
income-statement-row.row.income-tax-expense | 0 | -0.2 | -0.1 | -0.9 | |||||||
income-statement-row.row.net-income | 0 | 0.7 | 0.6 | 0.3 |
Dažnai užduodami klausimai
Kas yra Diaceutics PLC (DIUXF) bendras turtas?
Diaceutics PLC (DIUXF) bendras turtas yra 48256000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.796.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.027.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.027.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.061.
Kas yra Diaceutics PLC (DIUXF) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 724000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 1329000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 16166000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.